Filtered By:
Cancer: Cervical Cancer
Vaccination: Veterinary Vaccinations
This page shows you your search results in order of date.
Order by Relevance | Date
Total 564 results found since Jan 2013.
Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine
EMBO Mol Med. 2023 Sep 7:e17723. doi: 10.15252/emmm.202317723. Online ahead of print.ABSTRACTHuman papillomavirus (HPV) infections are the cause of all cervical and numerous oropharyngeal and anogenital cancers. The currently available HPV vaccines, which induce neutralizing antibodies, have no therapeutic effect on established tumors. Here, we developed an immuno-oncotherapy against HPV-induced tumors based on a non-integrative lentiviral vector encoding detoxified forms of the Early E6 and E7 oncoproteins of HPV16 and 18 genotypes, namely, "Lenti-HPV-07". A single intramuscular injection of Lenti-HPV-07 into mice bearing...
Source: Molecular Medicine - September 7, 2023 Category: Molecular Biology Authors: La ëtitia Douguet Ingrid Fert Jodie Lopez Benjamin Vesin Fabien Le Chevalier Fanny Moncoq Pierre Authi é Trang-My Nguyen Amandine Noirat Fabien N évo Catherine Blanc Maryline Bourgine David Hardy Fran çois Anna Laleh Majlessi Pierre Charneau Source Type: research
Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model
Vaccine. 2023 Jun 1:S0264-410X(23)00618-7. doi: 10.1016/j.vaccine.2023.05.057. Online ahead of print.ABSTRACTThe species and tissue specificities of HPV (human papillomavirus) for human infection and disease complicates the process of prophylactic vaccine development in animal models. HPV pseudoviruses (PsV) that carry only a reporter plasmid have been utilized in vivo to demonstrate cell internalization in mouse mucosal epithelium. The current study sought to expand the application of this HPV PsV challenge model with both oral and vaginal inoculation and to demonstrate its utility for testing vaccine-mediated dual-site i...
Source: Vaccine - June 3, 2023 Category: Allergy & Immunology Authors: Chelsea Sanders Rebecca L Matthews Sayyed Hamid Zarkesh Esfahani Nazneen Khan Nimit L Patel Joseph D Kalen Reinhard Kirnbauer Richard B Roden Simone Difilippantonio Ligia A Pinto Robert H Shoemaker Jason D Marshall Source Type: research
Fight Aging! Newsletter, January 2nd 2023
In conclusion, circulating monocytes in older adults exhibit increased expression of activation, adhesion, and migration markers, but decreased expression of co-inhibitory molecules.
MERTK Inhibition Increases Bone Density via Increased Osteoblast Activity
https://www.fightaging.org/archives/2022/12/mertk-inhibition-increases-bone-density-via-increased-osteoblast-activity/
Bone density results from the balance of constant activity on the part of osteoblasts and osteoclasts, the former building bone, the latter breaking it down. With advancing age, the balance of activity shifts to favor osteoclasts, prod...
Source: Fight Aging! - January 1, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine
CONCLUSION: We successfully constructed the HPV16/18/58 trivalent therapeutic adenovirus vaccine AD-HPV16/18/58 mE6E7. The AD-HPV16/18/58 mE6E7 adenovirus vaccine can protect immunized mice to a certain extent from TC-1, U14/LV-HPV18 E6E7 and U14/LV-HPV58 E6E7 cells, which contain HPV16, 18 and 58 E6 and/or E7 genes, respectively.PMID:35197089 | DOI:10.1186/s13027-022-00417-3
Source: Cancer Control - February 24, 2022 Category: Cancer & Oncology Authors: Bing Wan Lu Qin Weihong Ma He Wang Source Type: research
A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses
CONCLUSION: Our finding suggested that this novel fusion protein vaccine was able to induce therapeutic efficacy and immunogenicity by improving CD8 + T cell in TC-1 tumor bearing mice; so this vaccine may be appreciated for research against HPV and tumor immunotherapies.PMID:34313864 | DOI:10.1007/s10529-021-03166-2
Source: Biotechnology Letters - July 27, 2021 Category: Biotechnology Authors: Tahoora Mousavi Reza Valadan Alireza Rafiei Ali Abbasi Mohammad Reza Haghshenas Source Type: research
